Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(H Share Stock Code: 0874)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09 (2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Report for Absorption and Merger of Guangzhou Baiyunshan Pharmaceutical Co., Ltd. through Share Swap, Asset Acquisition through Issuance of Shares and Connected Transactions of Guangzhou Pharmaceutical Company Limited (Draft)(《廣州藥業股份有限公司換股吸收合 併廣州白雲山製藥股份有限公司、發行股份購買資產暨關聯交易報告書(草案)》), the opinion of the independent non-executive directors on the Major Assets Reorganization, the opinion of the independent non-executive directors of the Company on entering into and implementation of the Supplemental Agreement to the Trademark Custody Agreement (《商標托管協議書之補充 協議》) with Guangzhou Pharmaceutical Holdings Limited, the opinion of the Independent Financial Adviser on the Major Assets Reorganization, the Audit report, the Assessment Report of Proposed Assets Acquisition, Profit Forecasts in relation to the Proposed Merger of 2012 and Profit Forecasts of Asset Acquisition through Issuance of Shares of 2012 have been published on the website of The Shanghai Stock Exchange (www.sse.com.cn).

The Board of Guangzhou Pharmaceutical Company Limited

Guangzhou, the PRC, 18 June 2012

As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Li Chuyuan, Mr. Shi Shaobin (resigned on 18 June 2012) and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.